Filaggrin Mutation Status and Prevention of Atopic Dermatitis with Maternal Probiotic Supplementation
Acta Derm Venereol. 2024 Apr 24;104:adv24360. doi: 10.2340/actadv.v104.24360.ABSTRACTThe World Allergy Organization recommends probiotics in the prevention of atopic dermatitis in high-risk populations. Mutations in the filaggrin gene (FLG) result in an increased risk of atopic dermatitis through disruption of the skin keratin layer. This exploratory study investigated whether the preventive effect of maternal probiotics was evident in children with and without FLG mutations. DNA was collected from children (n = 228) from the Probiotic in the Prevention of Allergy among Children in Trondheim (ProPACT) study. Samples were a...
Source: Acta Dermato-Venereologica - April 24, 2024 Category: Dermatology Authors: Dinastry Pramadita Zakiudin Jacob P Thyssen Claus Zachariae Vibeke Videm Torbj ørn Øien Melanie Rae Simpson Source Type: research
Antibiotics within first year are linked to infant gut microbiome disruption and elevated atopic dermatitis risk
(Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - April 24, 2024 Category: Allergy & Immunology Authors: Courtney Hoskinson, Maria V. Medeleanu, Myrtha E. Reyna, Darlene LY. Dai, Biswajit Chowdhury, Theo J. Moraes, Piushkumar J. Mandhane, Elinor Simons, Anita L. Kozyrskyj, Meghan B. Azad, Charisse Petersen, Stuart E. Turvey, Padmaja Subbarao Source Type: research
Biologic and Small Molecule Therapy for Treating Moderate to Severe Atopic Dermatitis: Mechanistic Considerations
Atopic dermatitis (AD) is a complex and heterogeneous skin disease where achieving complete clinical clearance for most patients has proven challenging through single cytokine inhibition. Current studies integrate biomarkers and evaluate their role in AD, aiming to advance our understanding of the diverse molecular profiles implicated. While traditionally characterized as a Th2-driven disease, extensive research has recently revealed the involvement of Th1, Th17, and Th22 immune pathways, as well as the interplay of pivotal immune molecules, such as OX40, OX40 ligand (OX40L), thymic stromal lymphopoietin (TSLP), and IL-33....
Source: Journal of Allergy and Clinical Immunology - April 24, 2024 Category: Allergy & Immunology Authors: Camille Rothenberg-Lausell, Jonathan Bar, Dante Dahabreh, Yael Renert-Yuval, Ester del Duca, Emma Guttman-Yassky Source Type: research
Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways
CONCLUSIONS: Distinct immunologic ircAE endotypes suggest actionable targets for precision medicine-based interventions.PMID:38652814 | DOI:10.1158/1078-0432.CCR-23-3431 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 23, 2024 Category: Cancer & Oncology Authors: Mario E Lacouture Elena Goleva Neil Shah Veronica Rotemberg Lukas Kraehenbuehl Kwami F Ketosugbo Taha Merghoub Tara Maier Alexander Bang Stephanie Gu Trina Salvador Andrea P Moy Taras Lyubchenko Olivia Xiao Clifton F Hall Evgeny Berdyshev James Crooks Rya Source Type: research
Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways
CONCLUSIONS: Distinct immunologic ircAE endotypes suggest actionable targets for precision medicine-based interventions.PMID:38652814 | DOI:10.1158/1078-0432.CCR-23-3431 (Source: Cancer Control)
Source: Cancer Control - April 23, 2024 Category: Cancer & Oncology Authors: Mario E Lacouture Elena Goleva Neil Shah Veronica Rotemberg Lukas Kraehenbuehl Kwami F Ketosugbo Taha Merghoub Tara Maier Alexander Bang Stephanie Gu Trina Salvador Andrea P Moy Taras Lyubchenko Olivia Xiao Clifton F Hall Evgeny Berdyshev James Crooks Rya Source Type: research
Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study
CONCLUSIONS: Upadacitinib was therapeutically effective and tolerable for moderate-to-severe AD through 48 weeks in real-world clinical practice.PMID:38653561 | DOI:10.1080/09546634.2024.2344591 (Source: Herpes)
Source: Herpes - April 23, 2024 Category: Infectious Diseases Authors: Teppei Hagino Hidehisa Saeki Eita Fujimoto Naoko Kanda Source Type: research
Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study
CONCLUSIONS: Upadacitinib was therapeutically effective and tolerable for moderate-to-severe AD through 48 weeks in real-world clinical practice.PMID:38653561 | DOI:10.1080/09546634.2024.2344591 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - April 23, 2024 Category: Dermatology Authors: Teppei Hagino Hidehisa Saeki Eita Fujimoto Naoko Kanda Source Type: research
Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways
CONCLUSIONS: Distinct immunologic ircAE endotypes suggest actionable targets for precision medicine-based interventions.PMID:38652814 | DOI:10.1158/1078-0432.CCR-23-3431 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 23, 2024 Category: Cancer & Oncology Authors: Mario E Lacouture Elena Goleva Neil Shah Veronica Rotemberg Lukas Kraehenbuehl Kwami F Ketosugbo Taha Merghoub Tara Maier Alexander Bang Stephanie Gu Trina Salvador Andrea P Moy Taras Lyubchenko Olivia Xiao Clifton F Hall Evgeny Berdyshev James Crooks Rya Source Type: research
Adverse events in biologics for severe asthma
CONCLUSION: Biologics for severe asthma are recent drugs with a favorable safety profile, but with little real-life experience, justifying increased vigilance by prescribing physicians.PMID:38653607 | DOI:10.1016/j.rmr.2024.04.001 (Source: Revue des Maladies Respiratoires)
Source: Revue des Maladies Respiratoires - April 23, 2024 Category: Respiratory Medicine Authors: G Dargentolle M Georges G Beltramo C Poisson P Bonniaud Source Type: research
[[Translated article]]RF-Personalized Medicine to Treat Atopic Dermatitis: In Search for Predictive Biomarkers
Actas Dermosifiliogr. 2024 Apr 21:S0001-7310(24)00347-8. doi: 10.1016/j.ad.2024.04.007. Online ahead of print.NO ABSTRACTPMID:38653370 | DOI:10.1016/j.ad.2024.04.007 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - April 23, 2024 Category: Dermatology Authors: M A Lasheras-Perez F Navarro-Blanco M Rodriguez-Serna Source Type: research
Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study
CONCLUSIONS: Upadacitinib was therapeutically effective and tolerable for moderate-to-severe AD through 48 weeks in real-world clinical practice.PMID:38653561 | DOI:10.1080/09546634.2024.2344591 (Source: Herpes)
Source: Herpes - April 23, 2024 Category: Infectious Diseases Authors: Teppei Hagino Hidehisa Saeki Eita Fujimoto Naoko Kanda Source Type: research
Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study
CONCLUSIONS: Upadacitinib was therapeutically effective and tolerable for moderate-to-severe AD through 48 weeks in real-world clinical practice.PMID:38653561 | DOI:10.1080/09546634.2024.2344591 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - April 23, 2024 Category: Dermatology Authors: Teppei Hagino Hidehisa Saeki Eita Fujimoto Naoko Kanda Source Type: research
Adverse events in biologics for severe asthma
CONCLUSION: Biologics for severe asthma are recent drugs with a favorable safety profile, but with little real-life experience, justifying increased vigilance by prescribing physicians.PMID:38653607 | DOI:10.1016/j.rmr.2024.04.001 (Source: Revue des Maladies Respiratoires)
Source: Revue des Maladies Respiratoires - April 23, 2024 Category: Respiratory Medicine Authors: G Dargentolle M Georges G Beltramo C Poisson P Bonniaud Source Type: research
[[Translated article]]RF-Personalized Medicine to Treat Atopic Dermatitis: In Search for Predictive Biomarkers
Actas Dermosifiliogr. 2024 Apr 21:S0001-7310(24)00347-8. doi: 10.1016/j.ad.2024.04.007. Online ahead of print.NO ABSTRACTPMID:38653370 | DOI:10.1016/j.ad.2024.04.007 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - April 23, 2024 Category: Dermatology Authors: M A Lasheras-Perez F Navarro-Blanco M Rodriguez-Serna Source Type: research
Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study
CONCLUSIONS: Upadacitinib was therapeutically effective and tolerable for moderate-to-severe AD through 48 weeks in real-world clinical practice.PMID:38653561 | DOI:10.1080/09546634.2024.2344591 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - April 23, 2024 Category: Dermatology Authors: Teppei Hagino Hidehisa Saeki Eita Fujimoto Naoko Kanda Source Type: research
